TEV-45779

· Teva Pharmaceuticals USA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TEV-45779, covering 2025-10-07 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria [Phase 3]

See pricing